- Home
- CVAC vs DCTH Comparison
CVAC vs DCTH Comparison
Compare CVAC & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- DCTH
- Stock Information
- Founded
- CVAC 2000
- DCTH 1988
- Country
- CVAC Germany
- DCTH United States
- Employees
- CVAC N/A
- DCTH N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- CVAC Health Care
- DCTH Health Care
- Exchange
- CVAC Nasdaq
- DCTH Nasdaq
- Market Cap
- CVAC 764.4M
- DCTH 630.4M
- IPO Year
- CVAC 2020
- DCTH N/A
- Fundamental
- Price
- CVAC $4.47
- DCTH $16.21
- Analyst Decision
- CVAC Strong Buy
- DCTH Strong Buy
- Analyst Count
- CVAC 2
- DCTH 4
- Target Price
- CVAC $14.00
- DCTH $24.00
- AVG Volume (30 Days)
- CVAC 779.9K
- DCTH 610.5K
- Earning Date
- CVAC 05-20-2025
- DCTH 05-08-2025
- Dividend Yield
- CVAC N/A
- DCTH N/A
- EPS Growth
- CVAC N/A
- DCTH N/A
- EPS
- CVAC 0.87
- DCTH N/A
- Revenue
- CVAC $566,039,775.00
- DCTH $53,850,000.00
- Revenue This Year
- CVAC N/A
- DCTH $141.47
- Revenue Next Year
- CVAC $37.79
- DCTH $49.31
- P/E Ratio
- CVAC $5.16
- DCTH N/A
- Revenue Growth
- CVAC 787.60
- DCTH 1068.87
- 52 Week Low
- CVAC $2.37
- DCTH $6.33
- 52 Week High
- CVAC $5.28
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- CVAC 65.61
- DCTH 58.15
- Support Level
- CVAC $3.35
- DCTH $16.02
- Resistance Level
- CVAC $4.80
- DCTH $17.29
- Average True Range (ATR)
- CVAC 0.30
- DCTH 0.99
- MACD
- CVAC 0.07
- DCTH -0.03
- Stochastic Oscillator
- CVAC 77.51
- DCTH 49.63
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.